Zobrazeno 1 - 10
of 57
pro vyhledávání: '"Xiaowen Ge"'
Autor:
Danni Wu, Deliang Lu, Jiaojun Zhu, Xiaowen Ge, Jinxin Zhang, Litao Lin, Xiaoyu Wang, Huaqi Liu, Guangqi Zhang
Publikováno v:
Frontiers in Plant Science, Vol 14 (2023)
Forest gaps play an important role during forest succession in temperate forest ecosystems. However, the differences in spatial distribution and replacement patterns of woody plants (trees and shrubs) between primary and secondary forests remain uncl
Externí odkaz:
https://doaj.org/article/8b75ba67b05b498382f102c776b11c78
Autor:
Xiaowen Ge, Yiqun Du, Jianfeng Chen, Na Zhu, Jiamei Yao, Xin Zhang, Na Wang, Yujing Sun, Feng Gao, Weiguo Hu, Yingyong Hou
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundDrug resistance remains a serious challenge to rituximab therapy in B-NHL (B cell non-Hodgkin’s lymphoma). CDC (complement-dependent cytotoxicity) has been proposed as a major antitumor mechanism of rituximab, and direct abrogation of CD5
Externí odkaz:
https://doaj.org/article/abd6fd3dc3de40ffbae2b79c0eae1dbe
Autor:
Chen Xu, Yalan Liu, Xiaowen Ge, Dongxian Jiang, Ying Zhang, Yuan Ji, Jun Hou, Jie Huang, Jieakesu Su, Haiying Zeng, Jing Qin, Yingyong Hou
Publikováno v:
Diagnostic Pathology, Vol 12, Iss 1, Pp 1-11 (2017)
Abstract Background HER2 assessment in biopsy specimens of gastric cancer (GC) is challenging because of the intratumoral heterogeneity. False negative results may be get because of limited biopsy material. The aim of this study is to explore how tum
Externí odkaz:
https://doaj.org/article/08d3d15e42ae43e1984a937556d5f844
Autor:
Xuebin Qin, Jennifer R. Brown, Xu Li, Chun Wang, Stacey Fernandes, Weiguo Hu, Lin Wu, Xiaowen Ge
Purpose: Ofatumumab is an anti-CD20 antibody recently approved for treatment of fludarabine and alemtuzumab refractory chronic lymphocytic leukemia (CLL); it mediates much stronger complement-dependent cytotoxicity (CDC) than rituximab. Human CD59, a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0200b48383669331fb5e536be840f93f
https://doi.org/10.1158/1078-0432.c.6520286
https://doi.org/10.1158/1078-0432.c.6520286
Autor:
Xuebin Qin, Jennifer R. Brown, Jose A. Halperin, Bertal H. Aktas, Michael Chorev, Zhihai Peng, Gongxiong Wu, Jinyan Zhang, Ting Xu, Tao You, Xiaowen Ge, Weiguo Hu
Supplementary Figure 3 from Human CD59 Inhibitor Sensitizes Rituximab-Resistant Lymphoma Cells to Complement-Mediated Cytolysis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02de62c9b041d44ac32c88fe3c7f9292
https://doi.org/10.1158/0008-5472.22390961
https://doi.org/10.1158/0008-5472.22390961
Autor:
Xuebin Qin, Jennifer R. Brown, Jose A. Halperin, Bertal H. Aktas, Michael Chorev, Zhihai Peng, Gongxiong Wu, Jinyan Zhang, Ting Xu, Tao You, Xiaowen Ge, Weiguo Hu
Supplementary Materials and Methods from Human CD59 Inhibitor Sensitizes Rituximab-Resistant Lymphoma Cells to Complement-Mediated Cytolysis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9119103fa4899d70183c34f4dd03e0d2
https://doi.org/10.1158/0008-5472.22390946
https://doi.org/10.1158/0008-5472.22390946
Autor:
Xuebin Qin, Jennifer R. Brown, Jose A. Halperin, Bertal H. Aktas, Michael Chorev, Zhihai Peng, Gongxiong Wu, Jinyan Zhang, Ting Xu, Tao You, Xiaowen Ge, Weiguo Hu
Supplementary Figure 5 from Human CD59 Inhibitor Sensitizes Rituximab-Resistant Lymphoma Cells to Complement-Mediated Cytolysis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58060d593194ecbca325de2178189790
https://doi.org/10.1158/0008-5472.22390955.v1
https://doi.org/10.1158/0008-5472.22390955.v1
Autor:
Xuebin Qin, Jennifer R. Brown, Jose A. Halperin, Bertal H. Aktas, Michael Chorev, Zhihai Peng, Gongxiong Wu, Jinyan Zhang, Ting Xu, Tao You, Xiaowen Ge, Weiguo Hu
Supplementary Figure 4 from Human CD59 Inhibitor Sensitizes Rituximab-Resistant Lymphoma Cells to Complement-Mediated Cytolysis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7651fb5748c495a5d657c01d4d0a682e
https://doi.org/10.1158/0008-5472.22390958.v1
https://doi.org/10.1158/0008-5472.22390958.v1
Autor:
Xuebin Qin, Jennifer R. Brown, Jose A. Halperin, Bertal H. Aktas, Michael Chorev, Zhihai Peng, Gongxiong Wu, Jinyan Zhang, Ting Xu, Tao You, Xiaowen Ge, Weiguo Hu
Rituximab efficacy in cancer therapy depends in part on induction of complement-dependent cytotoxicity (CDC). Human CD59 (hCD59) is a key complement regulatory protein that restricts the formation of the membrane attack complex, thereby inhibiting in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::82ec89cf9b09ef241f2e8f9ef7f05fcb
https://doi.org/10.1158/0008-5472.c.6503108.v1
https://doi.org/10.1158/0008-5472.c.6503108.v1